Clinical trial NCT03884257: A Trial to Evaluate the Safety and Efficacy of the Passeo-18 Lux Drug-coated Balloon of Biotronik in the Treatment of the Femoropopliteal Artery Compared to the Medtronic IN.PACT Admiral Drug-coated Balloon.
Official title: A Randomized Controlled Non-inferiority Trial to Evaluate the Safety and Efficacy of the Passeo-18 Lux Drug-coated Balloon of Biotronik in the Treatment of Subjects with Stenotic, Restenotic or Occlusive Lesions of the Femoropopliteal Artery Compared to the Medtronic IN.PACT Admiral Drug-coated Balloon
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Peripheral Arterial Disease
Lead sponsor: ID3 Medical
Sponsor class: OTHER
First posted: 2019-03-21
Enrollment: 302
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: The patients will be assigned at random to one of two treatment groups namely the Passeo-18 Lux or the IN.PACT Admiral treatment group.
Primary purpose: TREATMENT

Brief summary: The BIOPACT RCT tiral investigates the efficacy and safety of stenosis, restenosis or occlusions in the femoropopliteal artery of patients presenting a rutherford classification 2,3 or 4 with a Passeo-18 Lux drug-coated balloon of Biotronik. The Paclitaxel eluting balloons are designed for percutaneous transluminal angioplasties in which the balloon will dilate the artery upon inflation and deliver the paclitaxel locally.

An expected total of 151 patients will be treated with the Passeo-18 Lux and compared to a control group of another 151 patients that will be treated with the IN.PACT Admiral drug-coated balloon of Medtronic. Assignment to the treatment groups will be at random. The study will be conducted in two phases. A first pilot study phase of 120 patients distributed evenly over both treatment groups and a second phase to formally test the non-inferiority hypothesis.

The balloon is coated with Paclitaxel intended to avoid cellular proliferation. The drug is released by means of rapid inflation as to release a high dose in a short amount of time. Patients will be invited for a follow-up visit at 1, 6 and 12 months post-procedure.

The primary efficacy endpoints are defined as follows. Freedom from clinically-driven target lesion revascularization at 12 months. Freedom from device- and procedure-related death through 30 days post-index procedure, major target limb amputation through 12 months post-procedure and clinically-driven target vessel revascularization through 12 months post-index procedure. The secondary endpoints are defined as acute device success, acute procedural success , freedom from all cause of death, major target limb amputation and clinically driven target vessel revascularisation through 30 days post-procedure, sustained clinical improvement, no major adverse events through 6 and 12 months post-procedure, primary patency, target lesion revascularisation, target vessel revascularisation, binary restenosis, major target limb amputation, thrombosis at target lesion, change of walking impairment questionnaire score from baseline, change in target limb rutherford classification or ABI.

Detailed description: The objective of this clinical investigation is to assess the safety and efficacy of the Passeo-18 Lux DCB for the treatment of stenotic, restenotic or occlusive lesions of the femoropopliteal arteries. Furthermore a non-inferiority hypothesis will be tested with the IN.PACT Admiral DCB as comparator.

The patients will be selected based on the investigator's assessment, evaluation of the underlying disease and the eligibility criteria. The patient's medical condition should be stable, with no underlying medical condition which would prevent them from performing the required testing or from completing the study. Patients should be geographically stable, willing and able to cooperate in this clinical study, and remain available for long term follow-up. The patient is considered enrolled in the study after obtaining the patients informed consent, if there is full compliance with the study eligibility criteria and after successful guidewire passage through the study target lesion.

Prior to the index procedure the following will be collected: an informed consent for data collection, demographics, medical history, medication record, physical examination, clinical category of acute limb ischemia (Rutherford category), the resting ankle-brachial index (ABI), blood sample test (complete blood count, comprehensive metabolic panel and if applicable pregnancy test) and a walking impairment questionnaire.

During the procedure the guidewire will cross the entire study lesion after which the lesion will be assessed through angiography. A pre-dilatation with a standard non-drug-coated balloon will be performed followed by a dilatation of the lesion with either a Passeo-18 Lux (Biotronik) or an IN.PACT Admiral balloon (Medtronic). If dilatation was not successful (\>30% stenosis, perforation, occlusive or flow limiting dissection) prolonged inflation should be attempted after which bail-out stenting with a bare nitinol stent is allowed in case of inadequate results.

The regular follow-up is necessary to monitor the condition of the patient and the results of the procedure. The patients will be invited for the following required follow-up visits at 1,6 and 12 months. During these visit the following data will be collected: medication record, physical exam, target limb ABI and Rutherford classification, duplex ultrasound of target vessel, walking impairment questionnaire and possible adverse events.

Eligibility criteria: Inclusion Criteria:

* Subject is ≥18 years
* Subject has Rutherford classification 2, 3 or 4
* Subject has provided written informed consent and is willing to comply with study follow- up requirements
* De novo stenotic or occlusive lesion(s) or non-stented restenotic or occlusive lesion(s) occurring \>90 days after prior plain old balloon (POBA) angioplasty or \>180 days after prior DCB treatment
* Target lesion is located between the ostium of the SFA and the end of the P1 segment of the popliteal artery
* Target vessel diameter ≥4mm and ≤7mm
* Target lesion must be stenotic lesion ≤180mm in length (one long lesion or tandem lesions) by investigator's visual estimate or a total occlusion ≤120mm in length by investigator's visual estimate.

Note: tandem lesions must have a total length of ≤180mm by visual estimate and be separated by ≤30mm

* Target lesion must have angiographic evidence of ≥70% stenosis by investigator's visual estimation
* Successful, uncomplicated crossing of the target lesion occurs when the tip of the guide wire is distal to the target lesion without the occurrence of flow-limiting dissection or perforation and is judged by visual inspection to be within the true lumen. Subintimal dissection techniques may be used if re-entry occurs above the knee (ATK) and without the use of re-entry devices
* Target lesion is located at least 30mm from any stent, if target vessel was previously stented
* After pre-dilatation, the target lesion is ≤50% residual stenosis, absence of a flow-limiting dissection and treatable with available device matrix
* A patent inflow artery free from significant stenosis (≥50% stenosis) as confirmed by angiography
* At least one patent native outflow artery to the ankle or foot, free from significant stenosis (≥50% stenosis) as confirmed by angiography

Exclusion Criteria:

* Acute limb ischemia
* Patient underwent an intervention involving the target vessel within the previous 90 days
* Patient underwent any lower extremity percutaneous treatment in the ipsilateral limb using a paclitaxel-eluting stent or DCB within the previous 90 days
* Patient underwent a percutaneous transluminal angioplasty (PTA) of the target lesion using a DCB within the previous 180 days
* Women who are pregnant, breast-feeding or intend to become pregnant
* Patient has life expectancy of less than 1 year
* Patient has a known allergy to contrast medium that cannot be adequately pre-medicated
* Patient is allergic to all antiplatelet treatments
* Patient is receiving immunosuppressant therapy
* Patient has platelet count \<100.000/mm3 or \>700.000/mm3
* Patient has history of gastrointestinal haemorrhage requiring a transfusion within 3 months prior to the study procedure
* Patient is diagnosed with coagulopathy that precludes treatment with systemic anticoagulation and/or dual antiplatelet therapy (DAPT)
* Patient has history of stroke within the past 90 days
* Patient has history of myocardial infarction within the past 30 days
* Patient is participating in an investigational drug or medical device study that has not completed primary endpoint(s) evaluation or that clinically interferes with the endpoints from this study, or patient is planning to participate in such study prior to the completion of this study
* Patient has had any major (e.g. cardiac, peripheral, abdominal) surgical procedure or intervention unrelated to this study within 30 days prior to the index procedure or has planned major surgical procedure or intervention within 30 days of the index procedure
* An intervention in the contralateral limb, planned within 30 days post-index procedure
* Patient had previous bypass surgery of the target lesion
* Patient had previous treatment of the target vessel with thrombolysis or surgery
* Patient is unwilling or unable to comply with procedures specified in the protocol or has difficulty or inability to return for follow-up visits as specified by the protocol
* Target lesion involves an aneurysm or is adjacent to an aneurysm (within 5mm)
* Target lesion requires treatment with alternative therapy such as stenting, laser, atherectomy, cryoplasty, brachytherapy or re-entry devices
* Significant target vessel tortuosity or other parameters prohibiting access to the target lesion
* Presence of thrombus in the target vessel
* Iliac inflow disease requiring treatment, unless the iliac artery disease is successfully treated first during the index procedure. Success is defined as ≤30% residual diameter stenosis without death or major complications
* Presence of an aortic, iliac or femoral artificial graft

Primary outcomes:
measure: freedom from clinically-driven target lesion revascularization (CD-TLR) at 12 months post-procedure
timeFrame: 12 months post-procedure
measure: Safety composite: number of participants who deceased, had major amputation, or target vessel revascularization (CD-TVR)
timeFrame: 12 months post-procedure
Secondary outcomes:
measure: acute device success
timeFrame: Index procedure
measure: acute procedural success
timeFrame: index procedure
measure: freedom from all causes of death, freedom from major target limb amputation and freedom from CD-TVR through 30 days
timeFrame: 1 month post-procedure
measure: Sustained clinical improvement
timeFrame: 6 and 12 months post-procedure
measure: freedom from major adverse events
timeFrame: 6 and 12 months post-procedure
measure: primary patency rate
timeFrame: 6 and 12 months post-procedure
measure: freedom from target lesion revascularisation
timeFrame: 6 and 12 months post-procedure
measure: freedom from target vessel revascularisation
timeFrame: 6 and 12 months post-procedure
measure: freedom from binary restenosis
timeFrame: 6 and 12 months post-procedure
measure: freedom from major target limb amputation
timeFrame: 6 and 12 months post-procedure
measure: freedom from thrombosis at target lesion
timeFrame: 6 and 12 months post-procedure
measure: change in walking impairment questionnaire score from baseline to 6 and 12 months
timeFrame: 6 and 12 months post-procedure
measure: change in target limb rutherford class from baseline to 6 and 12 months
timeFrame: 6 and 12 months post-procedure
measure: change in target limb resting ABI or TBI from baseline to 6 and 12 months
timeFrame: 6 and 12 months post-procedure
measure: freedom from all causes of death
timeFrame: 6 and 12 months post-procedure
Other outcomes:
Locations:
city: Graz
country: Austria
facility: Medical University of Graz
city: Vienna
country: Austria
facility: Hanusch Hospital
city: Aalst
country: Belgium
facility: OLV Ziekenhuis Aalst
state: Oost-Vlaanderen
city: Antwerp
country: Belgium
facility: UZA
city: Bonheiden
country: Belgium
facility: Imelda Hospital
city: Dendermonde
country: Belgium
facility: A.Z. Sint-Blasius
city: Genk
country: Belgium
facility: Z.O.L.
city: Tienen
country: Belgium
facility: R.Z. Heilig Hart
city: Bordeaux
country: France
facility: CHU Bordeaux
state: Nouvelle-Aquitaine
city: Toulouse
country: France
facility: Clinique Pasteur
state: Occitanie
city: Avignon
country: France
facility: Clinique Rhône Durance
state: Provence-Alpes-Côte d'Azur
city: Paris
country: France
facility: Hopital Paris Saint Joseph
city: Lausanne
country: Switzerland
facility: Centre Hospitalier Universitaire Vaudois
state: Vaud
city: Zürich
country: Switzerland
facility: Triemlispital Zürich
Study officials:
affiliation: AZ Sint-Blasius
name: Koen Deloose, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Deloose K, Lansink W, Brodmann M, Werner M, Keirse K, Goueffic Y, Verbist J, Maene L, Hendriks J, Brunet J, Ducasse E, Levent K, Sauguet A, Deglise S, Vandael F. Methodology of the BIOPACT RCT, a Multi-center, Randomized, Non-inferiority Trial Evaluating Safety and Efficacy of Passeo-18 Lux Drug-Coated Balloon (DCB) of Biotronik Compared to the Medtronic IN.PACT Admiral DCB in the Treatment of Subjects with Lesions of the Femoropopliteal Artery. Cardiovasc Intervent Radiol. 2022 Dec;45(12):1855-1859. doi: 10.1007/s00270-022-03259-z. Epub 2022 Sep 4.